Peripheral diabetic neuropathy and polyunsaturated fatty acid supplementations: natural sources or biotechnological needs?

The two essential fatty acids linoleic and alpha-linolenic acids, precursors of the n-6 and n-3 PUFA family, respectively, are known to play a strong regulatory function on cells via their incorporation into membrane phospholipids, and also on microcirculation by the production of eicosanoids. Moreover, diabetes mellitus induces impairment in PUFA metabolism due to an inhibition of desaturases, the enzymes involved in their synthesis. The decrease in PUFA bioavailability will conduct to marked alterations in membranes as well as impairment of the microcirculation. Those metabolic perturbations are involved in part in the degenerative complications of diabetes such as neuropathy. Nutritional supplementations with PUFA have given very interesting results in experimental diabetic neuropathy but also in human diabetic neuropathy. The gamma linolenic and arachidonic acids, members of the n-6 family, prevent the physiological abnormalities associated to neuropathy. The results obtained with the n-3 family PUFA are more discordant, probably because of the simultaneous use of eicosapentaenoic and docosahexaenoic acids. Nevertheless, the use of docosahexaenoic acid-enriched phospholipids produced positive results in the treatment of experimental diabetic neuropathy. These PUFA are available from natural sources but a biotechnological demand exists to provide these PUFA in different structural forms.